Levavi Hanoch
Division of Gynecologic Oncology, The Helen Schneider Hospital for Women, Rabin Medical Center, Petach Tikva;affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatr Endocrinol Rev. 2010 Sep;8(1):2-5.
Infection with the Human Papilloma Virus (HPV) is extremely common worldwide. Persistent infection with high-risk strains can lead to genital tract premalignant and malignant lesions. Two licensed prophylactic HPV vaccines against cervical malignancy are commercially available. In naive patients both vaccines showed close to 100% efficacy against persistent infection and genital disease associated with the vaccine-targeted HPV types, as well as excellent safety over several years of study. Here we present a discussion on the appropriate age and gender in which to propose vaccination, and conclude that the most suitable recommendation is for vaccination of adolescents.
人乳头瘤病毒（HPV）感染在全球极为常见。高危型毒株的持续感染可导致生殖道癌前病变和恶性病变。目前有两种已获许可的预防性HPV疫苗可用于预防宫颈癌，已投入商业使用。在初治患者中，两种疫苗对与疫苗靶向HPV类型相关的持续感染和生殖器疾病的预防效果接近100%，并且在数年的研究中显示出极佳的安全性。在此，我们讨论了建议接种疫苗的合适年龄和性别，并得出结论，最合适的建议是为青少年接种疫苗。
